Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy

References

• World Health Organization. 2018 Cancer fact sheet 2018, the global cancer observatory. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed August 15, 2018
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018;67(1):7–30. doi:10.3322/caac.21387
   Web of Science ®Google Scholar
• American Cancer Society Surveillance Research. Estimated deaths for the four major cancers by sex and age group. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/estimated-deaths-for-the-four-major-cancers-by-sex-and-age-group-2016.pdf. Published 2016 Accessed 713, 2018.
   Google Scholar
• Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91–112. doi:10.3322/caac.2010221303969
   PubMed Web of Science ®Google Scholar
• MacManus M, Everitt S, Schimek-Jasch T, Li XA, Nestle U, Kong F-M. (Spring) Translational lung cancer research. Transl Lung Cancer Res. 2017;6(6):670–688. Available from: http://tlcr.amegroups.com/article/view/16034/12985. Accessed September 22, 2018.29218270
   PubMed Web of Science ®Google Scholar
• Dobson Amato KA, Hyland A, Reed R, et al. Tobacco cessation may improve lung cancer patient survival. J Thorac Oncol. 2015;10(7):1014–1019. doi:10.1097/JTO.000000000000057826102442
   PubMedGoogle Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79. doi:10.1016/J.ADDR.2012.10.00223088862
   PubMed Web of Science ®Google Scholar
• Calixto G, Fonseca-Santos B, Chorilli M, Bernegossi J. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine. 2014;9(1):3719. doi:10.2147/IJN.S6167025143724
   PubMedGoogle Scholar
• Ruiz ME, Gantner ME, Talevi A. Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems). Recent Pat Anticancer Drug Discov. 2014;9(1):99–128. Available from: http://www.ingentaconnect.com/content/ben/pra/2015/00000010/00000001%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/23578193.23578193
   PubMed Web of Science ®Google Scholar
• Drbohlavova J, Chomoucka J, Adam V, et al. Nanocarriers for anticancer drugs–new trends in nanomedicine. Curr Drug Metab. 2013;14(5):547–564.23687925
   PubMed Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–10966. doi:10.1021/acs.chemrev.5b0004626010257
   PubMed Web of Science ®Google Scholar
• Danhier F, Préat V. Strategies to improve the EPR effect for the delivery of anti-cancer nanomedicines. Cancer Cell Microenviron. 2015;2(3):1–7. doi:10.14800/ccm.808
   Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107(23):10737–10742. doi:10.1073/pnas.100460410720498076
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163(1):34–45. doi:10.1016/j.jconrel.2012.06.00222698939
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 2014;8(9):1–32. doi:10.2217/nnm.13.118.Current
   Web of Science ®Google Scholar
• Lin C, Zhang X, Chen H, et al. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv. 2018;25(1):256–266. doi:10.1080/10717544.2018.142577729334814
   PubMed Web of Science ®Google Scholar
• Dicheva BM, Ten Hagen TLM, Schipper D, et al. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J Control Release. 2014;195:37–48. doi:10.1016/J.JCONREL.2014.07.05825176578
   PubMed Web of Science ®Google Scholar
• Al-Ahmady ZS, Chaloin O, Kostarelos K. Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release. 2014;196:332–343. doi:10.1016/J.JCONREL.2014.10.01325456832
   PubMed Web of Science ®Google Scholar
• Chi B, Wong K, Qin L, et al. Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Dovepress. 2014;8:993–1001.
   Google Scholar
• Lin C, Wong BCK, Chen H, et al. Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep. 2017;7(1):1097. doi:10.1038/s41598-017-00957-428428618
   PubMedGoogle Scholar
• Zhang X, Lin C, Lu A, et al. Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. Drug Deliv. 2017;24(1):986–998. doi:10.1080/10717544.2017.134036128644728
   PubMed Web of Science ®Google Scholar
• She Z, Zhang T, Wang X, et al. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid–octadecylamine conjugate. Biomaterials. 2014;35(19):5216–5225. doi:10.1016/J.BIOMATERIALS.2014.03.02224703714
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example In: Schafer-Korting M, editor. Handbook of Experimental Pharmacology. Berlin, Germany: Springer; Vol. 7 2010;3–53. doi: 10.1007/978-3-642-00477-3
   Google Scholar
• Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int J Mol Sci. 2018;19:1. doi:10.3390/ijms19010195
   Web of Science ®Google Scholar
• Riaz MK, Tyagi D, Yang Z. Surface engineering: incorporation of bioactive compound In: Yan B, Zhou H, Gardea-Torresdey JL, editors. Bioactivity of Engineered Nanoparticles. Singapore: Springer Nature; 2017:111–143. doi:10.1007/978-981-10-5864-6_6
   Google Scholar
• Han L, Huang R, Liu S, Huang S, Jiang C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm. 2010;7(6):2156–2165. doi:10.1021/mp100185f20857964
   PubMed Web of Science ®Google Scholar
• Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des. 1999;6:443–451.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291–317. doi:10.1016/j.bbagen.2011.07.01621851850
   PubMed Web of Science ®Google Scholar
• Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011;434(3):365–381. doi:10.1042/BJ2010182521348856
   PubMedGoogle Scholar
• Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci. 2006;29(5):367–374. doi:10.1016/j.ejps.2006.07.00416952451
   PubMed Web of Science ®Google Scholar
• Zhai G, Wu J, Yu B, Guo C, Yang X, Lee RJ. A transferrin receptor-targeted liposomal formulation for docetaxel. J Nanosci Nanotechnol. 2010;10(8):5129–5136. doi:10.1166/jnn.2010.239321125861
   PubMed Web of Science ®Google Scholar
• Lee JH, Engler JA, Collawn JF, Moore BA. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 2001;268(7):2004–2012. doi:10.1046/j.1432-1327.2001.02073.x11277922
   PubMedGoogle Scholar
• Wang Z, Zhao Y, Jiang Y, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015;5:12651. doi:10.1038/srep1265126219474
   PubMed Web of Science ®Google Scholar
• Oh S, Kim BJ, Singh NP, Lai H, Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 2009;274(1):33–39. doi:10.1016/j.canlet.2008.08.03118838215
   PubMed Web of Science ®Google Scholar
• Wu H, Yao L, Mei J, Li F. Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Med. 2014;7(12):4809–4818.25663977
   PubMed Web of Science ®Google Scholar
• Zong T, Mei L, Gao H, et al. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm. 2014;11(7):2346–2357. doi:10.1021/mp500057n24893333
   PubMedGoogle Scholar
• Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017;24(1):1045–1055. doi:10.1080/10717544.2017.134433428687044
   PubMed Web of Science ®Google Scholar
• Srivastava S, Somasagara RR, Hegde M, et al. Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci Rep. 2016;6:24049. doi:10.1038/srep2404927068577
   PubMed Web of Science ®Google Scholar
• Lu J, L V P, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 2006;66(8):4410–4418. doi:10.1158/0008-5472.CAN-05-331016618767
   PubMed Web of Science ®Google Scholar
• Del Follo-Martinez A, Banerjee N, Li X, Safe S, Mertens-Talcott S. Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr Cancer. 2013;65(3):494–504. doi:10.1080/01635581.2012.72519423530649
   PubMed Web of Science ®Google Scholar
• Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol. 1995;33(12):1061–1080. doi:10.1016/0278-6915(95)00077-18847003
   PubMed Web of Science ®Google Scholar
• Nguyen TTT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis. 2003;25(5):647–659. doi:10.1093/carcin/bgh05214688022
   PubMed Web of Science ®Google Scholar
• Xingyu Z, Peijie M, Dan P, et al. Quercetin suppresses lung cancer growth by targeting Aurora B kinase. Cancer Med. 2016;5(11):3156–3165. doi:10.1002/cam4.89127704720
   PubMed Web of Science ®Google Scholar
• Suntres ZE. Liposomal antioxidants for protection against oxidant-induced damage. J Toxicol. 2011;2011:152474. doi:10.1155/2011/15247421876690
   PubMedGoogle Scholar
• Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev. 2000;5(3):196–208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1086910110869101
   PubMedGoogle Scholar
• Kashyap D, Mittal S, Sak K, Singhal P, Tuli HS. Molecular mechanisms of action of quercetin in cancer: recent advances. Tumor Biol. 2016;37(10):12927–12939. doi:10.1007/s13277-016-5184-x
   PubMedGoogle Scholar
• Chou -C-C, Yang J-S, Lu H-F, et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch Pharm Res. 2010;33(8):1181–1191. doi:10.1007/s12272-010-0808-y20803121
   PubMed Web of Science ®Google Scholar
• Gang W, Jie WJ, Ping ZL, et al. Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo. Expert Opin Drug Deliv. 2012;9(6):599–613. doi:10.1517/17425247.2012.67992622607534
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tang J, Fu L, et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials. 2013;34(32):7980–7993. doi:10.1016/J.BIOMATERIALS.2013.07.01423891517
   PubMed Web of Science ®Google Scholar
• Liang D-S, Su H-T, Liu Y-J, Wang A-T, Qi X-R. Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials. 2015;71:11–23. doi:10.1016/J.BIOMATERIALS.2015.08.03526310359
   PubMed Web of Science ®Google Scholar
• Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res. 2003;9:5532–5539.
   Google Scholar
• Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. pharmaceutics. 2018;10(2):57. doi:10.3390/pharmaceutics10020057
   PubMed Web of Science ®Google Scholar
• Li H, Yuan D, Sun M, Ping Q. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo. Drug Deliv. 2016;23(9):3562–3572. doi:10.1080/10717544.2016.120979727432585
   PubMed Web of Science ®Google Scholar
• Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin VP. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv. 2018;25(1):517–532. doi:10.1080/10717544.2018.143574729433357
   PubMed Web of Science ®Google Scholar
• Ichim G, Tait SWG. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16(8):539–548. doi:10.1038/nrc.2016.5827364482
   PubMed Web of Science ®Google Scholar
• Nguyen TTT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis. 2004;25(5):647–659. doi:10.1093/carcin/bgh05214688022
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Pattni B, Torchilin V. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release. 2018;277(November2017):89–101. doi:10.1016/j.jconrel.2018.03.00629522834
   PubMedGoogle Scholar
• Liu Y, Ran R, Chen J, et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials. 2014;35(17):4835–4847. doi:10.1016/J.BIOMATERIALS.2014.02.03124651033
   PubMed Web of Science ®Google Scholar
• Mehta G, Hsiao YA, Ingram M, et al. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012;164(2):192–204. doi:10.1016/j.jconrel.2012.04.045.Opportunities22613880
   PubMed Web of Science ®Google Scholar
• Luo T, Loira-Pastoriza C, Patil HP, et al. PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. J Control Release. 2016;239:62–71. doi:10.1016/j.jconrel.2016.08.00827515664
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51. doi:10.1016/j.addr.2015.09.01226456916
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269(November2017):374–392. doi:10.1016/j.jconrel.2017.11.03629180168
   PubMedGoogle Scholar
• Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5(6):629–639. doi:10.1517/17425247.5.6.62918532919
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, NazilaKamaly OF. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi:10.1016/J.ADDR.2013.11.00924270007
   PubMed Web of Science ®Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9(1):467–483. doi:10.2147/IJN.S3665424531078
   PubMedGoogle Scholar
• Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 2017;31:15–30. doi:10.1016/j.drup.2017.05.00228867241
   PubMed Web of Science ®Google Scholar
• Dian L, Yu E, Chen X, et al. Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles. Nanoscale Res Lett. 2014;9(1):684. doi:10.1186/1556-276X-9-684
   PubMed Web of Science ®Google Scholar